Foghorn Therapeutics Inc. expected to post a loss of 25 cents a share - Earnings Preview

What happened

Foghorn Therapeutics is expected to report a 21.7% fall in quarterly revenue to $6.388 million from $8.15 million a year earlier, according to 10 analysts surveyed by LSEG. The company is also expected to post a loss of 25 cents a share.

Confirmed

Global impact / market context

A smaller revenue base means less money coming in to fund research and everyday operations, so the expected 25-cent loss could push the company to raise cash, cut spending, or slow programs. That directly affects how long its cash lasts and how investors value the shares.

Analyst inference

Analysts still rate the stock a buy on average, split between five buy or strong buy and five hold ratings, and the median 12-month price target of $5.00 sits far above the $2.09 last close. That gap suggests expectations rest on future progress, not current sales.

Analyst inference

What to watch

1. Watch whether reported revenue lands near the $6.388 million analyst estimate, since a bigger shortfall would mean less money coming in than analysts already expect. Confirmed
2. Watch for any company plan to raise new money or reduce research spending, because either step would change how long cash on hand lasts. Proposed
3. Watch whether analysts change their $5.00 median price target or buy ratings after results, since that would show whether their view of future prospects holds. Analyst inference

Evidence

• Original source link unavailable